logo-loader
viewCytoDyn Inc.

CytoDyn expects to exceed 75-patient enrollment in its coronavirus-focused Phase 2 clinical trial

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive its expects to exceed its 75 patient enrollment for a Phase 2 clinical trial of leronlimab for patients with mild-to-moderate symptoms of COVID-19.

Nader says the Washington-based biotech expects the evaluation of clinical patient data to be available two weeks after the last patient is enrolled. He also updated on its Phase 3 coronavirus-focused study.

Quick facts: CytoDyn Inc.

Price: 3.7599 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.95 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn reveals latest mild-to-moderate coronavirus patient data in Phase 2...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan says its drug leronlimab showed early clinical improvement in mild-to-moderate coronavirus patients in a recently completed Phase 2 trial. Pourhassan says in patients with a Total Clinical Symptom Score of 4 or more, with higher scores indicating...

2 days, 17 hours ago

2 min read